Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LGND stock price vs PSA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PSA's multiple
Needs PSA P/E.
Implied fair value · at LGND's multiple
Needs LGND P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Public Storage · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Royalty Pharma plc
LGND vs RPRX
Sarepta Therapeutics, Inc.
LGND vs SRPT
INCYTE CORP
LGND vs INCY
EXELIXIS, INC.
LGND vs EXEL
National Storage Affiliates Trust
LGND vs NSA
Prologis, Inc.
LGND vs PLD
WEYERHAEUSER CO
LGND vs WY
COSTAR GROUP, INC.
LGND vs CSGP
WELLTOWER INC.
LGND vs WELL
UDR, Inc.
LGND vs UDR
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LGND can sustain its 60.4% revenue growth and justify a persistent premium despite its 52.1x P/E, then hold or buy selectively; otherwise, the current price looks stretched versus PSA-like relative valuation and the DCF range.
LGND trades at a premium to PSA on every listed valuation multiple, yet the implied price of $224.30 sits 29.8% below the current price of $319.59. That gap is driven by LGND’s much higher P/E, P/S, EV/EBITDA, and EV/Revenue versus PSA, even though LGND has stronger revenue growth and a leaner balance sheet.
Supporting Metrics
